Based on the review, the researchers promote the integration of GLP-1 receptor agonists as a primary treatment for obesity in ...

The GLORIOUS trial found that an intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) during heart surgeries ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

In addition to ensuring equitable access to the glucagon-like peptide-1 (GLP-1) receptor agonists, the medical community ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

More information on the Phase 1 study can be found at www.clinicaltrials.gov, identifier NCT06036784. About MBX 1416 MBX 1416 is an investigational long-acting glucagon-like peptide-1 (GLP-1) receptor ...

About The Article: This Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA ...

HERSHEY, PA. — GLP-1 weight-loss drugs are having a “mild impact” on The Hershey Co.’s business, president and chief ...

With the rising popularity of telehealth providers offering GLP-1 medications like Ozempic, the terminology can get confusing ...

GLP-1RA prescription trends, real-world effectiveness, and predictors for access and rationing were highlighted at ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.